Prostate Checkup: PSA, Ultrasound and PVR Explained

A practical guide to prostate checks, PSA interpretation and urinary ultrasound in Dubai · 6 November 2026

A prostate checkup is more than a blood-test result marked “normal”. A useful assessment connects your symptoms, previous results, family history, prostate size and bladder emptying with a clear plan. The important question is not only “Is my PSA inside the laboratory range?” but also “What does this result mean for me, and what should happen next?”

Dr. Amin encourages men over 50 to discuss regular prostate-health reviews, including when an annual review is appropriate. The tests and their frequency should be tailored to the individual. A yearly consultation does not mean that every man needs the same blood tests and ultrasound every year.

What a checkup includes · Ultrasound and PVR · Understanding PSA · Your next steps · Common questions

Who should discuss a prostate checkup?

Do not wait for urinary symptoms to ask whether prostate cancer screening is appropriate for you. Early cancer may cause no symptoms. Equally, urinary symptoms do not automatically mean cancer: benign enlargement, infection and bladder problems are common explanations.

For men at average risk, the European Association of Urology recommends discussing early PSA testing from age 50. Earlier discussion is appropriate for some higher-risk men, including those with a family history, African ancestry or a relevant inherited gene variant. Age, general health, previous PSA and personal preferences help determine whether to test and when to repeat it. EAU: early detection and diagnostic assessment.

Before testing, discuss both the potential benefit of finding important cancer earlier and the risks of false alarms, further tests, and finding a slow-growing cancer that may never cause problems.

A clinical review also considers your urinary stream, night-time urination, urgency, discomfort, medication and relevant examination findings. Read more about prostate conditions and their different treatment pathways.

Blood and urine tests: what are they checking?

Investigations answer different questions. PSA concerns the prostate; urine testing and kidney-function tests can identify other reasons for symptoms or complications. BUN and creatinine are not “kidney hormones”, and PSA is a protein produced by prostate cells, not a hormone.

This is a discussion checklist, not a compulsory laboratory package for every symptom-free man. Dr. Amin selects the tests that are useful for your assessment. Bring earlier reports so that a new result can be interpreted in context. EAU: assessment of male urinary symptoms.

Urinary ultrasound: remember the post-void residual

When urinary-tract ultrasound is indicated, it can assess the kidneys, bladder and prostate. One particularly useful measurement is the post-void residual (PVR): the amount of urine left in the bladder after you urinate. This is different from measuring the bladder while it is full.

Check whether the referral specifically requests a post-void measurement. It is not included in every scan protocol. Tell the imaging team that bladder emptying is being assessed and follow their instructions about drinking and when to urinate. The bladder is measured again promptly after voiding. If PVR is absent from your report, ask your clinician whether it needs to be measured.

Ultrasound is not a stand-alone test for ruling out prostate cancer. Nor does PVR identify the cause of incomplete emptying by itself. A persistently raised residual may relate to prostate obstruction, urethral narrowing or a bladder muscle that does not contract effectively. Further assessment may include a urine-flow test or selected bladder-function tests. NIDDK: bladder-function and residual-urine testing.

A large prostate and a high PVR are different findings

A prostate volume of 40–50 mL can occur with benign enlargement in an older man, but it is not a universal definition of “normal”. A smaller prostate can cause significant symptoms, while a much larger one may cause relatively little trouble. Size alone does not determine whether medication or an operation is needed.

Likewise, a man with few symptoms and a modest prostate volume may still need assessment if his bladder repeatedly fails to empty well. Review the result rather than assuming that every high PVR is caused by the prostate. Our guide to benign prostate enlargement explains why symptoms and measurements must be considered together.

PSA: why the printed reference range is not the whole answer

There is no single PSA value that reliably separates cancer from non-cancer. Benign enlargement and inflammation can raise PSA; a result within the laboratory range does not exclude cancer. Interpretation also considers age, family history, previous measurements, examination, medication and prostate volume. National Cancer Institute: the PSA test.

Some prostate medicines, including finasteride and dutasteride, lower PSA and change how the result should be interpreted. Tell your urologist about all medicines, recent urinary infection or retention, and recent urinary procedures. Do not stop medication or start antibiotics simply to change a PSA number.

The same PSA can mean different things in different men

Consider two illustrative reports: a 60-year-old man with PSA 4 ng/mL and a 30 mL prostate, and a 70-year-old man with the same PSA but a 90 mL prostate. Neither report should be labelled safe or dangerous using age and size alone. The results need a personalized assessment.

One additional calculation is PSA density: total PSA divided by prostate volume. In these examples it is approximately 0.13 and 0.04 ng/mL/mL respectively. This helps explain why the same PSA is not interpreted identically in every patient. Density is one part of risk assessment, not a diagnosis or a guarantee that cancer is absent.

Free PSA: interpret the percentage, not just the separate number

The percentage of free PSA is calculated as free PSA divided by total PSA, multiplied by 100. For example, free PSA 1 ng/mL with total PSA 4 ng/mL gives 25%. In selected men with a borderline total PSA, a lower percentage can be associated with a greater likelihood of cancer.

A higher percentage is generally more reassuring in that context, but “above 20–25%” is not an all-clear rule, and a lower percentage is not a cancer diagnosis. It may help a clinician decide whether additional assessment is useful. The often-quoted 25% cutoff was studied in a specific group of patients; it is not a universal rule for every PSA result. Original multicentre study of percentage free PSA.

A rising PSA deserves review, not an automatic conclusion

If your PSA changes from 2 to 3 or 4 ng/mL over six months, bring both dated reports to your urologist even if the newer number is not flagged by the laboratory. A rise should be understood, including whether a temporary cause or a difference in testing conditions could explain it.

The rate of increase alone should not determine whether you need MRI or biopsy. An unexpected elevation may first be repeated at a clinician-selected interval. Repeat testing, risk assessment, MRI and sometimes biopsy have different roles; the appropriate next step depends on the complete picture. An MRI is not automatically necessary for everyone who has a rising PSA. AUA/SUO early-detection guideline: PSA trends and risk assessment.

What should you do with your results?

• Enlargement with troublesome symptoms: arrange a review to discuss the cause and treatment choices. Do not start prescription treatment without assessment.
• Raised PVR, even with few symptoms: ask whether the measurement needs confirmation and what may be affecting bladder emptying.
• An unexpected, persistent or rising PSA: take the full history of results to a urologist rather than relying only on the printed range or an automated interpretation.
• Blood in the urine, recurrent infection or abnormal kidney function: obtain medical assessment; these findings should not simply be attributed to ageing or benign enlargement.

Inability to pass urine, or fever with urinary symptoms and feeling unwell, needs urgent medical attention. For ongoing benign obstruction, the options may include monitoring, medicines or a procedure. Our comparison of Rezum, Aquablation, laser surgery, TURP and UroLift explains treatment choices after the cause has been established.

Why an experienced clinical review matters

The value of a consultation is the reasoning that connects the results to a decision. A careful review explains what is reassuring, what remains uncertain, and why a repeat test, imaging, treatment or observation is appropriate. This can help avoid both unnecessary procedures and delays in investigating a meaningful abnormality.

Ask your clinician: “How do my previous PSA, prostate volume, bladder emptying and family history affect this plan?” A second opinion can be useful if symptoms persist, results conflict, or you do not understand the recommended next step. An online tool can help explain terminology, but should not replace a clinician who can assess the full history and examine you when needed.

Early diagnosis of clinically significant cancer can offer more treatment choices. However, some low-risk cancers are managed with active surveillance rather than immediate treatment. Others require surgery, radiotherapy or combined treatment. Neither a guaranteed cure nor a low-cost outpatient operation can be promised from the stage alone. The aim is appropriate care at the right time. National Cancer Institute: prostate cancer treatment.

Common questions about prostate checkups

Do I need a checkup if I have no symptoms?

It is worth discussing prostate health and whether PSA screening is appropriate, especially from age 50 or earlier if your risk is higher. The schedule and tests should be agreed individually.

Can a normal ultrasound rule out prostate cancer?

No. Ultrasound can answer questions about size and the urinary tract, but a normal scan does not replace assessment of cancer risk.

Does PSA below 4 mean everything is normal?

No single cutoff gives that assurance. Previous results, medication, age and the rest of your assessment still matter.

Does residual urine mean I need prostate surgery?

No. The cause and significance must be assessed first. Incomplete emptying can have more than one explanation, and treatment is not selected from PVR alone.

What should I bring to the appointment?

Bring all previous PSA reports with dates and units, any free-PSA result, the ultrasound report including prostate volume and PVR if measured, urine and kidney-function tests, your medication list, and relevant family history. A short record of urinary symptoms is also useful.

Discuss your prostate results with Dr. Amin in Dubai

Dr. Amin Mir Sadeghi is a urologist and andrologist with more than 12 years of clinical and surgical experience. A consultation provides an opportunity to review your prostate and urinary investigations together, clarify whether further tests are needed, and discuss a treatment or monitoring plan suited to you.

Book a prostate assessment with Dr. Amin. Bring your existing reports so that the discussion starts with your results and concerns.